HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.7%

Neg 0% Neu 89.7% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.